Try our Advanced Search for more refined results

Janssen Biotech, Inc. et al v. Celltrion Healthcare Co., Ltd. et al

  1. March 03, 2017

    Judge Lays Out BPCIA 'Patent Dance' Rules

    Biosimilar makers must satisfy each step of the Biologics Price Competition and Innovation Act's "patent dance" if they hope to reduce damages that innovator companies can seek for infringement, a Massachusetts federal judge said in a newly released opinion.

  2. March 01, 2017

    Biosimilar Talks Needed To Trigger Litigation Clock: Judge

    A Massachusetts federal judge has ruled that biosimilar makers must engage in good-faith talks with innovator counterparts in order to trigger a litigation deadline for innovators to seek lost profits, according to representatives of Janssen Biotech and Pfizer.

  3. January 26, 2017

    Janssen Looks To Bar Sales Of Biosimilar In Remicade Suit

    Celltrion Healthcare should reimburse Janssen Biotech for all lost profits stemming from alleged infringement of a patent related to Janssen's arthritis treatment Remicade, the company told a Massachusetts federal court Wednesday, also calling for a nationwide ban on the sale of some versions of Celltrion's Remicade biosimilar, Inflectra.

  4. January 04, 2017

    J&J Says Pfizer Unit Jointly Liable In Remicade Patent Suit

    Johnson & Johnson unit Janssen Biotech Inc. told a Massachusetts federal court that Pfizer Inc. unit Hospira Inc. is more than a customer and should be held liable for patent infringement along with developer and licensor Celltrion Healthcare in two related cases over patents covering arthritis treatment Remicade.

  5. October 17, 2016

    Pfizer To Launch Biosimilar Of J&J's Top-Selling Remicade

    Drug giant Pfizer Inc. said Monday it will launch a cheaper, biosimilar version of Johnson & Johnson's blockbuster arthritis drug Remicade in late November, raising the stakes in the companies' ongoing legal battle over patents covering the drug.

  6. August 17, 2016

    Janssen Loses Fight To Keep Remicade Patent In Force

    A Massachusetts federal judge on Wednesday invalidated Janssen Biotech Inc.'s patent for the drug Remicade, handing a significant but not decisive victory to Celltrion Healthcare Co. Ltd. and Hospira Inc., which are looking to launch biosimilar versions of the $4 billion immunosuppressant drug in the United States this year.

  7. August 16, 2016

    Janssen Faces Mixed Prospects In Immuno Drug IP Suit

    A federal judge in Boston on Tuesday gave good news to both Janssen Biotech and Celltrion Healthcare in their dispute over a biosmilar version of Janssen's $4 billion-a-year immunosuppressant drug, saying while he is likely to declare one patent in the suit invalid, he would likely reject challenges to the other. Correction: A previous version of this story failed to clarify that the dispute over the '083 patent was a matter of claim construction. The error has been corrected.

  8. June 17, 2016

    Janssen Wants To Combine Celltrion Biosimilar Patent Suits

    Janssen Biotech Inc. on Thursday asked a Massachusetts federal court to combine two patent cases it's bringing against Celltrion Healthcare Co. and Hospira Inc. over Inflectra, the defendants' biosimilar of Janssen's blockbuster immunosuppressant Remicade.

  9. April 19, 2016

    Celltrion Rips Janssen's Bid to Move Up Biosimilar Trial Date

    Celltrion slammed Janssen Biotech's recent request for an earlier trial date in its patent infringement dispute over Celltrion's newly approved biosimilar Inflectra, telling a Massachusetts federal judge on Monday that there's no reason to change the current schedule.

  10. April 13, 2016

    Janssen Seeks Patent Trial To Halt Celltrion Biosimilar

    Janssen Biotech told a Massachusetts federal judge that it has “powerful evidence” showing patent infringement involving Celltrion’s newly approved biosimilar Inflectra and wants a trial later this year to block the drug's debut.